Peptide Profile
Adipotide
A targeted fat-destroying peptide that works like a smart missile, cutting off blood supply to fat cells and causing rapid weight loss in primate studies.
Dose Range
0.1-0.43mg/kg
Frequency
Once daily
Route
Subcutaneous injection
Cycle Length
4-6 weeks
Onset
Moderate (1-2 weeks)
Evidence
Strong
Compound Profile
Scientific & Efficacy Data
C111H206N36O28S2
Molecular Formula
2611.41 g/mol
Molecular Weight
Developed By · 2004
Wadih Arap and Renata Pasqualini
University of Texas MD Anderson Cancer Center
Primary Benefits
One of the most potent fat-reducing compounds studied in primates, working through direct destruction of fat tissue blood supply rather than metabolic pathways.
Significant improvements in insulin sensitivity and metabolic markers observed in all primate studies, with effects persisting beyond the treatment period.
Exceptionally fast-acting for a fat-loss compound, with measurable results appearing within 1-2 weeks and dramatic changes by week 4 of treatment.
Amino Acid Sequence
CKGGRAKDC-GG-D(KLAKLAK)2Dosing
How much
do I take?
Starting Dose
0.1 mg/kg
Begin with the lowest effective dose to assess tolerance and monitor kidney function. This cautious approach helps identify any sensitivity before progressing.
Standard Dose
0.25 mg/kg
This intermediate dose showed good efficacy with manageable side effects in primate studies. Regular monitoring of renal markers is essential.
Advanced Dose
0.43 mg/kg
The optimal therapeutic dose identified in primate studies. Produced average 11% body weight loss in 4 weeks. Requires close kidney monitoring and adequate hydration.
Timing
Best time to take
Morning, at a consistent time each day
With food?
Can be administered with or without food. Ensure adequate hydration throughout the day.
If stacking
If using BPC-157 for potential renal support, administer at a different time of day. Avoid combining with other nephrotoxic substances.
Adjusting Your Dose
Increase if
- +Tolerating current dose well with stable kidney markers
- +Minimal side effects after 1-2 weeks
- +Fat loss progress has plateaued at current dose
- +Serum creatinine remains within normal range
Decrease if
- -Serum creatinine rises above normal range
- -Significant proteinuria or glucosuria develops
- -Signs of dehydration despite adequate fluid intake
- -Any concerning changes in urination patterns
Signs of right dose
- ✓Steady fat loss of 2-3% body weight per week
- ✓Stable kidney function markers
- ✓Improved insulin sensitivity on bloodwork
- ✓No significant side effects
Dosing Calculator
Calculate Your Exact Dose
Amount to Draw
10
units
Suitability
Is this
right for me?
Best For
Targeted White Fat Reduction
Adipotide specifically seeks out and destroys the blood vessels feeding white adipose tissue. Unlike diet or exercise that shrink fat cells, this peptide actually eliminates fat tissue by cutting off its blood supply - a completely unique mechanism.
Stubborn Fat Deposits
Because it targets the vasculature of fat tissue directly, Adipotide may be particularly effective for stubborn fat deposits that resist traditional methods. The peptide homes in on prohibitin receptors found specifically on blood vessels supplying fat tissue.
Improving Insulin Resistance
Primate studies showed remarkable improvements in insulin sensitivity - treated monkeys used about 50% less insulin after treatment. This makes it interesting for research into obesity-related metabolic dysfunction.
Research Applications
As a pioneering vascular-targeting peptide, Adipotide represents a new class of potential therapeutics. Its unique mechanism of targeting specific tissue vasculature has implications beyond obesity research.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×You have any form of kidney disease or impaired renal function
- ×You are pregnant, trying to conceive, or breastfeeding
- ×You have a history of severe allergic reactions to peptides
- ×You are taking other nephrotoxic medications
- ×You have chronic dehydration or conditions affecting fluid balance
- ×You cannot commit to regular kidney function monitoring
Use with caution if
- !You are taking NSAIDs or other medications affecting kidney function
- !You have a history of kidney stones
- !You have diabetes (blood sugar monitoring needed)
- !You are over 65 years of age
- !You have cardiovascular conditions
- !You are taking diuretics or blood pressure medications
Administration
How do I
use it?
Reconstitution
What you need
- •Bacteriostatic water (BAC water)
- •Insulin syringe (29-31 gauge)
- •Alcohol swabs
- •Sterile vial of Adipotide powder
- •Calculator for dose calculation based on body weight
Injection
Route
Subcutaneous injection once daily
Best sites
- •Abdomen (2 inches from navel)
- •Front of thigh (middle third)
- •Upper arm (outer area)
Technique
- 1.Calculate your dose based on body weight and verify the math
- 2.Clean injection site thoroughly with alcohol swab and let dry
- 3.Pinch skin to create a fold at the injection site
- 4.Insert needle at 45-90 degree angle depending on body composition
- 5.Inject slowly and steadily
- 6.Remove needle and apply light pressure - do not rub
Storage
Signs of degradation
Safety
Is it
safe?
Safety Profile
Adipotide has been extensively studied in mice, rats, and three species of primates with consistent results. The primary safety concern is dose-dependent kidney effects, which were reversible upon stopping treatment in all studies. No cardiovascular, neurological, or hepatic adverse events were observed. The compound shows remarkable selectivity - lean animals given the same doses experienced no weight loss, suggesting it specifically targets excess fat tissue.
Safety data comes from well-designed primate studies published in peer-reviewed journals including Science Translational Medicine. However, there are no human clinical trials, so the full safety profile in humans remains unknown. The reversibility of kidney effects in primates is encouraging but requires validation in human studies.
Common Side Effects
Experienced by some users
Elevated Serum Creatinine
The most consistently observed effect in primate studies, indicating the kidneys are processing the compound.
Management: Monitor with regular blood tests. Usually normalizes within 4 weeks of stopping treatment. Stay well-hydrated.
Proteinuria
Mild to moderate protein appearing in urine, reflecting kidney filtration changes.
Management: Monitor with urinalysis. Reduce dose if marked. Ensure adequate hydration.
Glucosuria
Glucose appearing in urine even with normal blood sugar, due to effects on kidney tubules.
Management: Monitor blood glucose to ensure it remains normal. Not typically concerning if blood sugar is stable.
Reduced Appetite
Decreased food intake observed in all treated animals - appears to be genuine appetite reduction rather than nausea.
Management: Ensure adequate protein intake despite reduced appetite. This effect contributes to weight loss.
Less Common
- •Mild Dehydration
- •Injection Site Reactions
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Serum creatinine rises significantly above your baseline
- ×Marked proteinuria that persists or worsens
- ×Signs of kidney problems (pain in lower back, changes in urination)
- ×Severe or persistent dehydration despite adequate fluid intake
- ×Any allergic reaction (rash, swelling, difficulty breathing)
- ×Completion of the recommended 4-week treatment cycle
Adipotide is a research compound without FDA approval. Use only under medical supervision with regular kidney function monitoring. Stop immediately and consult a healthcare provider if you experience any concerning symptoms.
Interactions
With other peptides
- ✓May provide protective effects for kidneys - consider using for support
- ✓No known interactions, but avoid adding kidney stress
- !Both target fat loss through different mechanisms - use caution with combination
- !Different mechanisms but overlapping goals - not recommended to combine
With medications
- !NSAIDs (Ibuprofen, etc.) - Can compound kidney stress - avoid during Adipotide use
- !ACE Inhibitors - May affect kidney function - monitor closely if combining
- !Diuretics - Increases dehydration risk significantly - avoid combination
- ✓Metformin - Generally safe but monitor kidney function more frequently
With supplements
- ✓Electrolytes - Highly recommended to maintain proper hydration and mineral balance
- ✓Protein supplements - Recommended to preserve muscle mass during rapid fat loss
- ✓Creatine - May confound creatinine monitoring - consider stopping during treatment
- ✓High-dose Vitamin C - Very high doses may affect kidney stone risk - use moderate amounts
Effectiveness
Does it
work?
Evidence Level
Strong preclinical
What to Expect
Week 1
What you might notice
- •Possible slight decrease in appetite
- •No dramatic weight changes yet
- •Injection site may have minor redness
- •Increased thirst as body adjusts
What's normal
- •Mild elevation in creatinine on blood tests
- •Slight changes in urination patterns
- •Body weight relatively stable
What's next
- →Continue monitoring kidney function
- →Maintain excellent hydration
- →Prepare to assess tolerance for dose increase
Week 2-3
What you might notice
- •Noticeable reduction in appetite
- •Beginning of measurable weight loss (3-7%)
- •Clothes may start fitting differently
- •Possible increase in energy as fat decreases
What's normal
- •Steady weight loss of 2-3% per week
- •Continued mild kidney marker changes
- •Reduced food intake without feeling ill
What's next
- →Continue at current dose if tolerating well
- →Mid-cycle kidney function check recommended
- →Ensure protein intake remains adequate
Week 4
What you might notice
- •Significant fat loss visible (7-15% body weight reduction)
- •Waist circumference noticeably reduced
- •Improved metabolic markers on bloodwork
- •Better insulin sensitivity
What's normal
- •Total weight loss of 10-15% from baseline
- •Peak kidney marker changes
- •Appetite significantly reduced from baseline
What's next
- →Complete the treatment cycle
- →Schedule post-treatment kidney function tests
- →Plan recovery period of at least 4 weeks
Recovery (Week 5-8)
What you might notice
- •Kidney markers returning to normal
- •Appetite gradually returning
- •Weight may stabilize at new lower level
- •Improved metabolic health may persist
What's normal
- •Creatinine normalizing within 2-4 weeks
- •Some appetite recovery
- •Maintained fat loss if diet is controlled
What's next
- →Confirm kidney function fully normalized
- →Focus on maintaining results through diet
- →Assess if another cycle is appropriate after full recovery
Signs It's Working
Fat Loss Progress
- ✓Steady decrease in body weight (2-3% per week at optimal dose)
- ✓Reduction in waist and abdominal circumference
- ✓Visible reduction in subcutaneous fat
- ✓Clothes fitting looser, especially around midsection
- ✓DEXA or body composition scans showing fat mass decrease
Metabolic Improvements
- ✓Lower fasting insulin levels on bloodwork
- ✓Improved insulin sensitivity markers
- ✓Better fasting glucose readings
- ✓Reduced inflammatory markers
- ✓Improved lipid profile
Appetite and Behavior
- ✓Naturally reduced appetite without nausea
- ✓Feeling satisfied with smaller meals
- ✓Reduced cravings for high-calorie foods
- ✓More stable energy throughout the day
Not Seeing Results?
Common reasons
- •Dose too low - the therapeutic dose of 0.43 mg/kg was needed for optimal results in primates
- •Not enough time - significant results require 3-4 weeks of consistent use
- •Poor quality peptide - ensure sourcing from reputable research suppliers
- •Inadequate hydration - dehydration can stress kidneys and reduce effectiveness
- •Inconsistent dosing - daily administration is important for maintaining tissue levels
- •Already lean - the peptide specifically targets excess fat and shows less effect in lean subjects
Key Research
"Reversal of obesity by targeted ablation of adipose tissue"
Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W, 2004
Finding: This foundational study discovered that the CKGGRAKDC peptide homes to white fat blood vessels by binding prohibitin. When linked to a cell-death-inducing sequence, it caused targeted destruction of fat tissue and rapid obesity reversal in mice without detectable side effects.
View Study"A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys"
Barnhart KF, Christianson DR, Hanley PW, et al., 2011
Finding: Obese rhesus monkeys lost an average of 11% body weight in just 4 weeks of treatment. MRI confirmed 17-27% reduction in white adipose tissue. Treated monkeys showed 50% improvement in insulin sensitivity. Kidney effects were predictable and fully reversible.
View Study"Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma"
Kolonin MG, Pasqualini R, Arap W, 2011
Finding: This study validated the peptide screening platform used to discover Adipotide and demonstrated how targeting specific vascular markers can be used therapeutically. The approach has implications beyond obesity for targeted drug delivery.
View Study"Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium Reduces Food Intake and Body Weight"
Kim DH, Woods SC, Seeley RJ, 2010
Finding: Confirmed that the proapoptotic peptide targeting fat vasculature reduces food intake in addition to directly destroying fat tissue. This dual mechanism may contribute to its effectiveness for weight loss.
View StudyFrequently Asked Questions